To develop new methods to distinguish indolent from aggressive prostate cancers (PCa), we
utilized comprehensive high-throughput array-based relative methylation (CHARM) assay to …

African American (AA) men have the highest incidence and mortality rate from Prostate
cancer (PCa) than any other racial/ethnic group. To date, PCa genomic studies have largely …

Background Current diagnostic tools for prostate cancer lack specificity and sensitivity for
detecting very early lesions. DNA methylation is a stable genomic modification that is …

Although genome-wide association studies (GWAS) for prostate cancer (PrCa) have
identified more than 100 risk regions, most of the risk genes at these regions remain largely …

Prostate cancer (PCa) is the second most common cancer in men and is a highly heritable
disease that affects millions of individuals worldwide. Genome-wide association studies …

Background Patients with metastatic prostate cancer (PC) are treated with androgen
deprivation therapy (ADT) that initially reduces metastasis growth, but after some time lethal …

BACKGROUND Altered DNA methylation in CpG islands of gene promoters has been
implicated in prostate cancer (PCa) progression and can be used to predict disease …

Background: The role of methylation in pancreatic cancer risk remains unclear. We
integrated genome and methylome data to identify CpG sites (CpG) with the genetically …

Background Expression quantitative trait locus (eQTL) analysis has emerged as an
important tool in elucidating the link between genetic variants and gene expression, thereby …

Tumor DNA circulates in the plasma of cancer patients admixed with DNA from
noncancerous cells. The genomic landscape of plasma DNA has been characterized in …